Itron.png
Water Distribution System in Perth Receives Upgrade with Itron’s Multi-Vendor Meter Data Management Solution
18 déc. 2024 18h00 HE | Itron, Inc.
Itron announced that it’s working together with Water Corporation to modernize the utility’s water distribution system.
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
12 sept. 2024 16h56 HE | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
Integra diventa il p
Integra diventa il primo Itron Engage Sales Channel Partner in Italia
12 juin 2024 08h45 HE | Itron, Inc.
LIBERTY LAKE, Wash., June 12, 2024 (GLOBE NEWSWIRE) -- Itron, Inc. (NASDAQ: ITRI), che propone modalità innovative per le Aziende per la distribuzione dell’energia (Utilitiies) e le Municipalità per...
Integra Becomes Firs
Integra Becomes First Itron Engage Sales Channel Partner in Italy
12 juin 2024 08h45 HE | Itron, Inc.
Integra S.R.L. to help utilities and cities in Italy enhance their grid infrastructure with Itron’s solutions.
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
27 févr. 2024 15h52 HE | BioAegis Therapeutics
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
16 oct. 2023 14h40 HE | BioAegis Therapeutics
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Oct....
TIP_link_300x300.jpg
Autonomous Mobile Manipulator Robots Market worth $2,099.63 Million by 2030 - Exclusive Report by The Insight Partners
28 août 2023 09h21 HE | The Insight Partners
Pune, India, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The adoption of AMMR is increasing owing to the rise in automation in the warehouse and manufacturing industries. Further, the rise in demand for chips...
ContraFect_LOGO_Web.jpg
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
28 août 2023 08h00 HE | ContraFect Corporation
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
OpGen.jpg
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
10 août 2023 16h15 HE | OpGen, Inc.
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D...
OpGen.jpg
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
03 août 2023 07h30 HE | OpGen, Inc.
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...